Research Alliance Corp III

The filing confirms trust value at $10.00 per share ($75,000,000) and the 24-month deadline (May 2028). No business combination target has been selected or discussed. The material weakness in disclosure controls is a red flag for internal governance. Sponsor conduct includes standard promissory note repayment and founder share issuance. Conversion mechanics: Founder shares (Class B) convert to Class A at 15% of post-IPO shares. No working capital loans outstanding but $3,000,000 facility available. Redemption features are standard. The company has a working capital deficit pre-IPO but expects sufficient funds post-IPO.

This filing establishes the definitive trust value ($75,000,000) and hard redemption/liquidation deadline (May 21, 2028). According to Note 1, management has selected no specific business combination target and has engaged in no substantive discussions with any prospective acquirer. Consequently, there are no immediate deal timelines, amendment proposals, or extension votes on the horizon; investors instead face a pure execution phase where the Company must locate, vet, and secure a target using the disclosed $1,255,049 post-IPO cash reserve. The documented sponsor and underwriter waivers structurally cap downside risk during a failed liquidation scenario, preserving the maximum possible return to public redemptions. Investors monitoring trust erosion or dilution should watch for future filings regarding convertible working capital loans (up to $3,000,000 at $10.00 per share) or changes to the independent director composition, as both could alter capital structure dynamics before the 2028 expiration.

This filing establishes the baseline trust value of $10.00 per public share, the redemption deadline, the founder share lock-up period (one year after business combination or earlier upon share price trigger), and the sponsor's agreement to vote in favor of any business combination. It also confirms that the company intends to focus on a healthcare target. Investors can now track trust value, monitor extension votes, and assess sponsor conduct against the commitments disclosed.

Structural economics create severe sponsor alignment risks: the sponsor acquired founder shares for $25,000 ($0.02 per share) and will see those stakes become worthless absent a transaction, incentivizing acceptance of suboptimal targets. Officers and directors owe primary fiduciary duties to RA Capital Management, which the prospectus notes holds 'over $15 billion of regulatory assets under management as of December 31, 2025' and operates multiple competing investment vehicles. Consequently, the filing discloses that 'investment ideas generated within or presented to RA Capital Management...

The filing provides definitive terms for the SPAC’s IPO, including trust size ($75M, $10/share), 24-month deadline to complete a business combination, sponsor compensation (founder shares at ~$0.02/share, private placement of 275,000 shares at $10), redemption mechanics, and lock-up provisions. The upsizing and share capitalization indicate strong sponsor commitment and potential dilution considerations. Investors should note the deadline for a business combination is 24 months from closing, and there is no limit on extensions if shareholder-approved.

For investors tracking the redemption calendar, this filing establishes the core terms that will govern once the IPO closes: $10.00 per public share in trust; redemption at the initial business combination equal to the trust account per-share amount; a 15% per-beneficial-owner redemption cap if shareholder approval is used; a 24-month completion deadline from IPO closing; and extension votes with redemption rights. The trust agreement permits disbursement only under a termination letter countersigned by Leerink, for tax payments, for shareholder redemptions, and for up to $300,000 per year of interest for working capital. It also bears on sponsor conduct and economics: the sponsor paid $25,000 for 1,014,706 founder shares, or approximately $0.02 per share, of which 132,353 are forfeitable if the over-allotment option is not exercised; the sponsor will buy 695,000 private placement shares, or 702,500 if the over-allotment option is exercised in full, at $10.00 per share; up to $3,000,000 of working capital loans may convert at $10.00 per share; and the sponsor has a non-binding indication to purchase up to $100.0 million of shares at the de-SPAC. The underwriter receives $0.40 per share total compensation, including $0.30 per share deferred until a business combination, and Leerink has a right of first refusal on de-SPAC financings with a fee equal to the greater of $2.0 million or 1% of proceeds raised, excluding RA Capital proceeds. Strategically, the sponsor is an affiliate of RA Capital Management, which the prospectus says had over $15 billion of regulatory assets under management as of December 31, 2025, and the company plans to focus on healthcare-related targets; prior affiliated SPACs include Research Alliance Corp I, which merged with POINT Biopharma and was later acquired by Eli Lilly, and Research Alliance Corp II, which liquidated. There is no de-SPAC progress here: no target selected, no substantive discussions, and no change to the 24-month deadline.

This filing provides the foundational disclosure for investors to evaluate the SPAC's IPO. It specifies the trust mechanics, sponsor compensation (founder shares at nominal cost), potential dilution through founder share conversion anti-dilution rights, conflict-of-interest risks, and the 24-month window to complete a de-SPAC. The detailed risk factors, use of proceeds, and dilution tables allow investors to assess the economics and governance of the offering. No target has been identified; the SPAC has not initiated substantive discussions with any business combination candidate.

What changed: Quarterly report (Form 10-Q) for a blank check company (SPAC) covering the period ended June 30, 2026, including financial statements and a subsequent business combination agreement with OHB Pediatrics Ltd. The company consummated its IPO on May 21, 2026, deposited $75 million into trust, and subsequently on July 26, 2026, entered into a business combination agreement with OHB Pediatrics Ltd. The filing also reveals a material weakness in internal controls and a going concern uncertainty. Why it matters: Investors need to know the trust value ($75,238,468 at June 30, 2026, $10 per share), the pending deal details (including backstop and PIPE), the material weakness, and the going concern risk. The redemption deadline is 2028 but the deal is expected to close in H2 2026.

What changed: An SEC Form 425 filing transmitting a social media post from Oak Hill Bio and referenced third-party press articles covering a proposed merger/business combination between Research Alliance Corp III (RACC) and Oak Hill Bio (OHB Pediatrics Ltd). The filing advances the transaction timeline by disclosing a Business Combination Agreement dated July 26, 2026, between RACC and Oak Hill Bio. Oak Hill Bio CEO Josh Distler announced via the attached social media post that the merged entity will list on Nasdaq under the ticker symbol OAKH with a closing expected by the end of 2026. Deal mechanics detail that RACC’s trust account will contribute $75 million to the combined company, layered with $100 million in committed private financing from RA Capital and other investors, producing $175 million in launch cash. The filing also notes a separate $32.5 million Series A raise designated for the lead asset rugonersen. Regarding governance and voting procedures, the filing states RACC intends to file a registration statement on Form S-4 containing preliminary and definitive proxy statements to be mailed to RACC shareholders for solicitation, with a record date to be established. No amendments to the existing redemption calendar, trust maintenance provisions, deadline extensions, or sponsor conduct protocols were disclosed in this communication. Why it matters: The disclosure materially defines the capital stack funding the de-SPAC, pairing $75 million from the SPAC trust with $100 million in private placement capital, which may affect initial listing liquidity and warrant exercise dynamics relative to trusts funded solely by public proceeds. Clinically, the filing updates the development trajectory: Distler confirmed the Phase 3 BEACON trial for rugonersen dosed its first patient as of early August 2026, with a primary completion date and potential NDA submission both targeted for 2029. This sequencing positions the asset behind competing antisense oligonucleotide programs from Ultragenyx Pharmaceutical and Ionis Pharmaceuticals, both running Phase 3 trials; Distler noted Ultragenyx anticipates results this year, while observing that in the therapeutic space, participants often face pressure to be first or best. Commercial and demographic parameters are outlined by Oak Hill Bio stating Angelman syndrome affects approximately 1 in 15,000 births and impacts roughly 500,000 patients globally. Asset history reveals Roche initiated a Phase 1 trial in 2020 but shelved rugonersen in 2023 after the Foundation for Angelman Syndrome Therapeutics conveyed the drug failed to meet Roche’s efficacy targets; Oak Hill Bio subsequently licensed the molecule in April 2025. Corporate lineage indicates Takeda spun out Oak Hill in 2022, Distler is slated to remain as CEO of the combined company, and RACC director Matthew Hammond publicly endorsed the transaction as combining compelling science with experienced leadership. Investors should track the forthcoming S-4 filing for definitive proxy voting logistics, redemption thresholds, and any sponsor support agreements tied to the public float.

What changed: Schedule 13G beneficial ownership report. The filing identifies Bank of America Corp /DE/ as the reporting holder but contains no narrative, share counts, transaction dates, or percentages. It therefore records no updates to redemption windows, trust accounting rules, extension procedures, merger execution milestones, or sponsor actions. Why it matters: This is a routine regulatory disclosure. Because the document provides no operational details or numerical thresholds, it does not accelerate shareholder exit options, modify capital preservation structures, signal timeline adjustments for the announced transaction, or reflect sponsor conduct shifts. It merely satisfies periodic institutional reporting requirements without impacting the SPAC’s corporate trajectory.

What changed: A Rule 425 filing submitting a LinkedIn post shared on July 28, 2026, by Timothy J. Miller, independent director of RACC, announcing the execution of a Business Combination Agreement dated July 26, 2026 with OHB Pediatrics Ltd., and directing investors to the forthcoming Form S-4 registration statement. No updates are provided to the redemption calendar, trust account value per share, or extension provisions. The filing simply advances deal progress by confirming the July 26, 2026 agreement date and establishing that RACC intends to file a Form S-4 containing preliminary and definitive proxy statements before mailing voting materials to shareholders of record. Why it matters: While it alters no redemption mechanics or trust terms, it materially shifts the transaction into the formal SEC disclosure and shareholder solicitation phase. Per the post, RACC and OHB Pediatrics management project market size and growth potential, outline expectations for clinical trial initiation, completion, and data readout timing, cite potential product candidate approval pathways, identify financing and business milestones, and acknowledge supply chain and raw material sourcing dependencies. The filing also explicitly notes that the 'amount of redemption requests made by RACC’s public shareholders' remains a cited risk factor that could adversely affect the combined company or expected benefits. Investors must now track the S-4 filing for definitive economic structures and the official voting/redemption cutoff schedule.

What changed: Rule 425 filing by Research Alliance Corporation III (RACC) disseminating LinkedIn posts from OHB Pediatrics Ltd. executives and providing standard disclosures regarding the proposed business combination. The Business Combination Agreement between RACC and OHB Pediatrics Ltd. was entered into on July 26, 2026. This filing confirms the deal and includes social media posts from the target's CEO, CFO, CMO, CSO, and COO promoting the transaction. No changes to trust value, redemption deadline, extensions, or sponsor conduct were disclosed in this filing. Why it matters: This filing provides formal confirmation that a definitive business combination agreement has been signed, moving the SPAC from a target announcement to a binding deal. The LinkedIn posts indicate the target's leadership is actively promoting the combination, which could influence shareholder sentiment. The filing also serves as a reminder that a registration statement on Form S-4 will be filed, and shareholders should review that document for detailed information.

What changed: A Schedule 13D/A amendment to a beneficial ownership report, identified by submission marker [0002135648-26-000011]. The provided text contains no operational updates regarding RACC’s redemption calendar, trust account valuation, extension mechanisms, business combination trajectory, or sponsor conduct; the structured holder table that would ordinarily detail shifts in percentage ownership, block transfers, or financing accommodations is explicitly flagged as absent in this XML variant. Why it matters: Because the tabular disclosures are missing, the excerpt generates zero attributable claims concerning prospective customers, revenue projections, total addressable market, technology roadmaps, partnership configurations, litigation posture, or management transitions. Correlating the circulation timestamp of 2026-07-28 with the statutory business combination expiration of 2028-05-21 yields no new procedural signals regarding capital deployment or shareholder return thresholds. Without the underlying row-level data, the filing cannot substantiate dilution estimates, warrant exercise windows, or sponsor promote vesting schedules. Analysts must retrieve the complete exhibit to verify whether the 13D/A functions as a routine cyclical update or a corrective filing.

What changed: 8-K filed by Research Alliance Corp III (RACC) announcing entry into a definitive Business Combination Agreement with OHB Pediatrics Ltd. (Oak Hill Bio), a clinical-stage rare disease biotech developing rugonersen for Angelman syndrome. RACC signed a Business Combination Agreement to acquire OHB Pediatrics. Key deal terms: base equity value $160M, adjusted by $45M SAFE (8% PIK) from RA Capital. Total committed financing of $100M ($45M SAFE + $55M PIPE at $10.00/share). Trust account holds approximately $75M (per share price $10.00); redemptions fully backstopped by RA Capital via Backstop Agreement for up to $75M. Closing expected in second half of 2026. RACC will domesticate from Cayman to Delaware. Public shareholders have redemption rights. Sponsor and certain shareholders subject to 6-month lock-up. Post-closing company renamed Oak Hill Bio, Inc., ticker OAKH on Nasdaq. Target's lead candidate rugonersen is in Phase 3 BEACON trial; first patient dosed July 2026. Target expects cash runway through NDA filing in 2H2029. Why it matters: This is the definitive business combination announcement, the most critical event for a SPAC. It provides the target, valuation ($160M base), financing structure ($100M), trust mechanics ($10.00/share with backstop), redemption deadlines (vote with S-4), shareholder vote, and post-close ownership. The filing includes all ancillary agreements (sponsor letter, SAFE, backstop, PIPE subscription, investor rights, lock-up) and an investor presentation with market estimates (~$4-5B AS market, ~30k patients). It also describes sponsor conduct: RA Capital provides both SAFE and backstop, aligning incentives. The extensive business and financial details allow investors to evaluate the deal.

What changed: Business combination agreement and related agreements, filed as Form 8-K under Rule 425, announcing a definitive merger between Research Alliance Corporation III (RACC) and OHB Pediatrics Ltd. (Oak Hill Bio), a clinical-stage rare disease company. RACC entered into a definitive Business Combination Agreement on July 26, 2026 to acquire OHB Pediatrics Ltd. (Oak Hill Bio). Key terms: Base equity value of Oak Hill Bio $160M; Adjusted Equity Value includes a $45M SAFE from RA Capital; Closing consideration = Adjusted Equity Value / $10.00 per share. RACC trust account had at least $75M as of the date; redemption rights provided; fully backstopped up to $75M by RA Capital Healthcare Fund (Backstop Agreement). PIPE financing of $55M at $10.00 per share. Closing expected second half 2026. Termination date initially January 26, 2027, extendable to April 26, 2027 if certain conditions remain unmet. Post-closing company to be named Oak Hill Bio, Inc., trading under ticker OAKH on Nasdaq. Why it matters: This is the definitive business combination agreement that sets the deal structure, valuation, financing, and timeline. Investors should monitor the shareholder vote, redemption deadline, and the backstop which reduces the risk of large redemptions draining the trust. The filing also contains detailed representations and warranties about the target's business, pipeline (rugonersen for Angelman syndrome), and regulatory status. The trust value is $10.00 per share and the backstop ensures any redemptions are covered up to $75M.

What changed: Quarterly report (10-Q) for the period from inception (February 19, 2026) through March 31, 2026, filed after the IPO closed on May 21, 2026. This is the first periodic report since the IPO. It establishes baseline financials: no operations, net loss of $65,249, cash of $280,275, working capital deficit of $490,291. It describes the IPO completed on May 21, 2026: 7,500,000 Class A shares at $10.00 per share, gross proceeds $75,000,000, offering costs $3,727,251 (including $2,250,000 deferred underwriting). Simultaneous private placement of 275,000 Class A shares at $10.00 per share, gross proceeds $2,750,000. Trust account funded with $75,000,000 ($10.00 per share). Sponsor loan of $300,000 repaid from IPO proceeds. Also discloses a material weakness in internal control over financial reporting related to classification of expenses. Why it matters: The filing confirms trust value at $10.00 per share ($75,000,000) and the 24-month deadline (May 2028). No business combination target has been selected or discussed. The material weakness in disclosure controls is a red flag for internal governance. Sponsor conduct includes standard promissory note repayment and founder share issuance. Conversion mechanics: Founder shares (Class B) convert to Class A at 15% of post-IPO shares. No working capital loans outstanding but $3,000,000 facility available. Redemption features are standard. The company has a working capital deficit pre-IPO but expects sufficient funds post-IPO.

What changed: A Joint Filing Agreement (Exhibit 99.1) attached to a Schedule 13D regulatory submission, executed on May 29, 2026, by Research Alliance Holdings III LLC and Matthew Hammond. The document stipulates that the two named filers will combine their reporting obligations for RACC Class A ordinary shares, par value $0.0001 per share, into a single Schedule 13D under SEC Rule 13(d)(1)(k). It specifies that either party may terminate the arrangement upon one week’s prior written notice. The text contains no data regarding redemption deadlines, trust account balances, extension votes, target merger progress, or sponsor conduct, leaving all mechanical parameters unaddressed by this exhibit. Why it matters: Because the filing serves exclusively as a procedural wrapper for ownership disclosure, it signals coordinated administrative handling between the sponsor entity and its manager rather than operational or financial developments. No claims about customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel are present. Investors tracking RACC’s redemption calendar or capital deployment should look to the primary Schedule 13D body or separate SPAC filings, as this agreement alters neither the trust composition nor the stated timeline. Attributed entirely to the filing parties, the document confirms only their mutual consent to streamline regulatory submissions and carries no standalone pricing or voting directives.